@entity65 of multi- XXXX kinase inhibitors in advanced solid @entity5 : a population-based observational study.

@entity1 @entity64 @entity2240 @entity63 @entity5 @entity2857 @entity951 @entity741 @entity204 @entity583 @entity4149 @entity65 @entity3866
BACKGROUND: Treatment with small molecule @entity4149 kinase inhibitors (TKIs) has improved survival in many @entity5 , yet has been associated with an increased risk of adverse events. Warnings of cardiovascular events are common in drug labels of many TKIs. Despite these warnings, @entity65 of @entity1 treated with TKIs remains unclear. Here, we evaluate the cardiovascular outcomes of @entity5 @entity1 treated with small molecule @entity4149 kinase inhibitors. METHODS: A population based cohort study was undertaken involving adults aged >18 years in Ontario, Canada, diagnosed with any advanced malignancy between 2006 and 2012. Data were extracted from linked administrative governmental databases. Adults with @entity5 receiving TKIs were identified and followed throughout the time period. The main outcomes of interest were rates of hospitalization for @entity741 ( @entity583 and @entity951 ) or @entity64 and @entity204 . RESULTS: 1642 @entity1 with a mean age of 62.5 years were studied; 1046 were treated with @entity3866 , 166 with @entity2857 and 430 with @entity2240 . Over the 380 day median follow-up period (range 6-1970 days), 1.1% of all @entity1 had @entity63 heart events, 0.7% had @entity64 and 72.1% died. Rates of cardiovascular events were similar to age and gender-matched individuals without @entity5 . In a subgroup analysis of treatment @entity1 with a prior history of @entity741 , 3.3% had @entity63 heart events while 1.2% had @entity64 . CONCLUSIONS: TKIs do not appear to increase the cause-specific hazard of @entity741 and @entity64 compared to age and gender-matched individuals without @entity5 .
